Clarity Pharmaceuticals Ltd

Quick facts

Phase 3 pipeline

• 64Cu-SAR-bisPSMA · Oncology
  64Cu-SAR-bisPSMA is a copper-64 labeled radiopharmaceutical that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.

Phase 1 pipeline

• 67Cu-SAR-bisPSMA · Oncology
  PSMA-targeting radioligand
• Cu-64 SARTATE and Cu-67 SARTATE

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Clarity Pharmaceuticals Ltd portfolio CI brief
• Clarity Pharmaceuticals Ltd pipeline updates RSS